-
1
-
-
34548383480
-
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension
-
G. Mancia, G. De Backer, A. Dominiczak 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension J Hypertens 25 2007 1751 1762
-
(2007)
J Hypertens
, vol.25
, pp. 1751-1762
-
-
Mancia, G.1
De Backer, G.2
Dominiczak, A.3
-
2
-
-
77952304034
-
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)
-
T. Ogihara, K. Kikuchi, H. Matsuoka The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009) Hypertens Res 32 2009 3 107
-
(2009)
Hypertens Res
, vol.32
, pp. 3-107
-
-
Ogihara, T.1
Kikuchi, K.2
Matsuoka, H.3
-
3
-
-
57349138291
-
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
-
K. Jamerson, M.A. Weber, G.L. Bakris Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients N Engl J Med 359 2008 2417 2428
-
(2008)
N Engl J Med
, vol.359
, pp. 2417-2428
-
-
Jamerson, K.1
Weber, M.A.2
Bakris, G.L.3
-
4
-
-
0035818884
-
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
-
J.N. Cohn, G. Tognoni A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N Engl J Med 345 2001 1667 1675
-
(2001)
N Engl J Med
, vol.345
, pp. 1667-1675
-
-
Cohn, J.N.1
Tognoni, G.2
-
5
-
-
0242490542
-
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
-
M.A. Pfeffer, J.J. McMurray, E.J. Velazquez Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
-
(2003)
N Engl J Med
, vol.349
, pp. 1893-1906
-
-
Pfeffer, M.A.1
McMurray, J.J.2
Velazquez, E.J.3
-
6
-
-
0035922444
-
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
-
H.H. Parving, H. Lehnert, J. Brochner-Mortensen The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes N Engl J Med 345 2001 870 878
-
(2001)
N Engl J Med
, vol.345
, pp. 870-878
-
-
Parving, H.H.1
Lehnert, H.2
Brochner-Mortensen, J.3
-
7
-
-
0034100147
-
Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases
-
S. Kim, H. Iwao Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases Pharmacol Rev 52 2000 11 34
-
(2000)
Pharmacol Rev
, vol.52
, pp. 11-34
-
-
Kim, S.1
Iwao, H.2
-
8
-
-
52049105198
-
Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition
-
E. Yamamoto, Y.F. Dong, K. Kataoka Olmesartan prevents cardiovascular injury and hepatic steatosis in obesity and diabetes, accompanied by apoptosis signal regulating kinase-1 inhibition Hypertension 52 2008 573 580
-
(2008)
Hypertension
, vol.52
, pp. 573-580
-
-
Yamamoto, E.1
Dong, Y.F.2
Kataoka, K.3
-
9
-
-
67650567354
-
Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: A study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients
-
(no. NCT 00134160)
-
H. Ogawa, S. Kim-Mitsuyama, T. Jinnouchi Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials.gov, no. NCT 00134160) Hypertens Res 32 2009 575 580
-
(2009)
Hypertens Res
, vol.32
, pp. 575-580
-
-
Ogawa, H.1
Kim-Mitsuyama, S.2
Jinnouchi, T.3
-
10
-
-
33748918856
-
Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004)
-
Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004) Hypertens Res 29 Suppl 2006 S1 S105
-
(2006)
Hypertens Res
, vol.29
, Issue.SUPPL.
-
-
-
11
-
-
1642464732
-
Azelnidipine and amlodipine: A comparison of their pharmacokinetics and effects on ambulatory blood pressure
-
K. Kuramoto, S. Ichikawa, A. Hirai Azelnidipine and amlodipine: a comparison of their pharmacokinetics and effects on ambulatory blood pressure Hypertens Res 26 2003 201 208
-
(2003)
Hypertens Res
, vol.26
, pp. 201-208
-
-
Kuramoto, K.1
Ichikawa, S.2
Hirai, A.3
-
12
-
-
36348939350
-
Statistics in medicine-reporting of subgroup analyses in clinical trials
-
R. Wang, S.W. Lagakos, J.H. Ware Statistics in medicine-reporting of subgroup analyses in clinical trials N Engl J Med 357 2007 2189 2194
-
(2007)
N Engl J Med
, vol.357
, pp. 2189-2194
-
-
Wang, R.1
Lagakos, S.W.2
Ware, J.H.3
-
13
-
-
43549100189
-
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study
-
S.G. Chrysant, M. Melino, S. Karki The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study Clin Ther 30 2008 587 604
-
(2008)
Clin Ther
, vol.30
, pp. 587-604
-
-
Chrysant, S.G.1
Melino, M.2
Karki, S.3
-
14
-
-
73849138948
-
A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: The REZALT study
-
T. Ogihara, T. Saruta, K. Shimada, K. Kuramoto A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study Hypertens Res 32 2009 1148 1154
-
(2009)
Hypertens Res
, vol.32
, pp. 1148-1154
-
-
Ogihara, T.1
Saruta, T.2
Shimada, K.3
Kuramoto, K.4
-
15
-
-
2942635317
-
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
-
S. Julius, S.E. Kjeldsen, M. Weber Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031
-
(2004)
Lancet
, vol.363
, pp. 2022-2031
-
-
Julius, S.1
Kjeldsen, S.E.2
Weber, M.3
-
16
-
-
38549181561
-
Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan antihypertensive survival evaluation in Japan trial
-
T. Ogihara, K. Nakao, T. Fukui Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial Hypertension 51 2008 393 398
-
(2008)
Hypertension
, vol.51
, pp. 393-398
-
-
Ogihara, T.1
Nakao, K.2
Fukui, T.3
-
17
-
-
0344373794
-
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
-
(2002)
JAMA
, vol.288
, pp. 2981-2997
-
-
-
18
-
-
0037108235
-
Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: Current practice and problems
-
S.J. Pocock, S.E. Assmann, L.E. Enos, L.E. Kasten Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems Stat Med 21 2002 2917 2930
-
(2002)
Stat Med
, vol.21
, pp. 2917-2930
-
-
Pocock, S.J.1
Assmann, S.E.2
Enos, L.E.3
Kasten, L.E.4
-
19
-
-
0026911107
-
Prospective randomized open blinded end-point (PROBE) study A novel design for intervention trials. Prospective Randomized Open Blinded End-Point
-
L. Hansson, T. Hedner, B. Dahlof Prospective randomized open blinded end-point (PROBE) study A novel design for intervention trials. Prospective Randomized Open Blinded End-Point Blood Press 1 1992 113 119
-
(1992)
Blood Press
, vol.1
, pp. 113-119
-
-
Hansson, L.1
Hedner, T.2
Dahlof, B.3
|